A common docking domain in progesterone receptor-B links DUSP6 and CK2 signaling to proliferative transcriptional programs in breast cancer cells

Nucleic Acids Research

Volumn 41, Issue 19, 2013, Pages 8926-8942

  Hagan, Christy R ^a   Knutson, Todd P ^a   Lange, Carol A ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASEIN KINASE II; DUAL SPECIFICITY PHOSPHATASE 6; GESTAGEN; JANUS KINASE; PROGESTERONE RECEPTOR B; STAT PROTEIN; STAT5 PROTEIN; WNT1 PROTEIN;

AMINO TERMINAL SEQUENCE; ARTICLE; BREAST CANCER; CANCER CELL; CELL CYCLE PROGRESSION; CELL CYCLE S PHASE; CONTROLLED STUDY; ENHANCER REGION; ENZYME INHIBITION; GENE EXPRESSION; GENE TARGETING; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION;

BREAST NEOPLASMS; CASEIN KINASE II; CELL LINE, TUMOR; CELL PROLIFERATION; DUAL SPECIFICITY PHOSPHATASE 6; ENHANCER ELEMENTS, GENETIC; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; JANUS KINASES; PHOSPHORYLATION; PROGESTINS; PROTEIN INTERACTION DOMAINS AND MOTIFS; RECEPTORS, PROGESTERONE; S PHASE; SERINE; SIGNAL TRANSDUCTION; STAT TRANSCRIPTION FACTORS; STAT5 TRANSCRIPTION FACTOR; TRANSCRIPTION, GENETIC; WNT1 PROTEIN;

EID: 84885961937     PISSN: 03051048     EISSN: 13624962     Source Type: Journal    
DOI: 10.1093/nar/gkt706     Document Type: Article

References (97)

1. Kraus, W.L., Montano, M.M. and Katzenellenbogen, B.S. (1993) Cloning of the rat progesterone receptor gene 5′-region and identification of two functionally distinct promoters. Mol. Endocrinol., 7, 1603-1616.
2. Kastner, P., Krust, A., Turcotte, B., Stropp, U., Tora, L., Gronemeyer, H. and Chambon, P. (1990) Two distinct estrogenregulated promoters generate transcripts encoding the two functionally different human progesterone receptor forms A and B. EMBO J., 9, 1603-1614.
3. Kastner, P., Krust, A., Turcotte, B., Stropp, U., Tora, L., Gronemeyer, H. and Chambon, P. (1990) Two distinct estrogen-regulated promoters generate transcripts encoding the two functionally different human progesterone receptor forms A and B. EMBO J., 9, 1603-1614.
4. Hill, K.K., Roemer, S.C., Churchill, M.E. and Edwards, D.P. (2012) Structural and functional analysis of domains of the progesterone receptor. Mol. Cell. Endocrinol., 348, 418-429.
5. Sartorius, C.A., Melville, M.Y., Hovland, A.R., Tung, L., Takimoto, G.S. and Horwitz, K.B. (1994) A third transactivation function (AF3) of human progesterone receptors located in the unique N-terminal segment of the B-isoform. Mol. Endocrinol., 8, 1347-1360.
6. Owen, G.I., Richer, J.K., Tung, L., Takimoto, G. and Horwitz, K.B. (1998) Progesterone regulates transcription of the p21(WAF1) cyclin-dependent kinase inhibitor gene through Sp1 and CBP/p300. J. Biol Chem, 273, 10696-10701.
7. Stoecklin, E., Wissler, M., Schaetzle, D., Pfitzner, E. and Groner, B. (1999) Interactions in the transcriptional regulation exerted by Stat5 and by members of the steroid hormone receptor family. J. Steroid Biochem. Mol. Biol., 69, 195-204.
8. Cicatiello, L., Addeo, R., Sasso, A., Altucci, L., Petrizzi, V.B., Borgo, R., Cancemi, M., Caporali, S., Caristi, S., Scafoglio, C. et al. (2004) Estrogens and progesterone promote persistent CCND1 gene activation during G1 by inducing transcriptional derepression via c-Jun/c-Fos/estrogen receptor (progesterone receptor) complex assembly to a distal regulatory element and recruitment of cyclin D1 to its own gene promoter. Mol. Cell. Biol., 24, 7260-7274.
9. McKenna, N.J., Lanz, R.B. and O'Malley, B.W. (1999) Nuclear receptor coregulators: cellular and molecular biology. Endocrine Rev., 20, 321-344.
10. Daniel, A.R., Faivre, E.J. and Lange, C.A. (2007) phosphorylation dependent antagonism of sumoylation de-represses progesterone receptor action in breast cancer cells. Mol. Endocrinol., 21, 2890-2906.
11. Lange, C.A., Shen, T. and Horwitz, K.B. (2000) Phosphorylation of human progesterone receptors at serine-294 by mitogen-activated protein kinase signals their degradation by the 26S proteasome. Proc. Natl Acad. Sci. USA, 97, 1032-1037.
12. Weigel, N.L., Bai, W., Zhang, Y., Beck, C.A., Edwards, D.P. and Poletti, A. (1995) Phosphorylation and progesterone receptor function. J. Steroid. Biochem. Mol. Biol., 53, 509-514.
13. Knutson, T.P., Daniel, A.R., Fan, D., Silverstein, K.A., Covington, K.R., Fuqua, S.A. and Lange, C.A. (2012) Phosphorylated and sumoylation-deficient progesterone receptors drive proliferative gene signatures during breast cancer progression. Breast Cancer Res., 14, R95.
14. Daniel, A.R., Gaviglio, A.L., Czaplicki, L.M., Hillard, C.J., Housa, D. and Lange, C.A. (2011) The progesterone receptor hinge region regulates the kinetics of transcriptional responses through acetylation, phosphorylation, and nuclear retention. Mol. Endocrinol., 24, 2126-2138.
15. Pierson-Mullany, L.K. and Lange, C.A. (2004) Phosphorylation of progesterone receptor serine 400 mediates ligandindependent transcriptional activity in response to activatoin of cyclin-dependent protein kinase2. Mol. Cell. Biol., 24, 10542-10557.
16. Meggio, F. and Pinna, L.A. (2003) One-thousand-and-one substrates of protein kinase CK2? FASEB J., 17, 349-368.
17. Tawfic, S., Yu, S., Wang, H., Faust, R., Davis, A. and Ahmed, K. (2001) Protein kinase CK2 signal in neoplasia. Histol. Histopathol., 16, 573-582.
18. Zhang, Y., Beck, C.A., Poletti, A., Edwards, D.P. and Weigel, N.L. (1994) Identification of phosphorylation sites unique to the B form of human progesterone receptor. In vitro phosphorylation by casein kinase II. J. Biol. Chem., 269, 31034-31040.
19. Hagan, C.R., Regan, T.M., Dressing, G.E. and Lange, C.A. (2011) ck2-dependent phosphorylation of progesterone receptors (PR) on Ser81 regulates pr-β isoform-specific target gene expression in breast cancer cells. Mol. Cell. Biol, 31, 2439-2452.
20. Guerra, B. and Issinger, O.G. (2008) Protein kinase CK2 in human diseases. Curr. Med. Chem., 15, 1870-1886.
21. Hagan, C.R., Faivre, E.J. and Lange, C.A. (2009) Scaffolding actions of membrane-associated progesterone receptors. Steroids, 74, 568-572.
22. Ballare, C., Uhrig, M., Bechtold, T., Sancho, E., Di Domenico, M., Migliaccio, A., Auricchio, F. and Beato, M. (2003) Two domains of the progesterone receptor interact with the estrogen receptor and are required for progesterone activation of the c-Src/Erk pathway in mammalian cells. Mol. Cell. Biol., 23, 1994-2008.
23. Boonyaratanakornkit, V., Scott, M.P., Ribon, V., Sherman, L., Anderson, S.M., Maller, J.L., Miller, W.T. and Edwards, D.P. (2001) Progesterone receptor contains a proline-rich motif that directly interacts with SH3 domains and activates c-Src family tyrosine kinases. Mol. Cell, 8, 269-280.
24. Cerliani, J.P., Guillardoy, T., Giulianelli, S., Vaque, J.P., Gutkind, J.S., Vanzulli, S.I., Martins, R., Zeitlin, E., Lamb, C.A. and Lanari, C. (2011) Interaction between FGFR-2, STAT5, and progesterone receptors in breast cancer. Cancer Res., 71, 3720-3731.
25. Richer, J.K., Lange, C.A., Manning, N.G., Owen, G., Powell, R. and Horwitz, K.B. (1998) Convergence of progesterone with growth factor and cytokine signaling in breast cancer. Progesterone receptors regulate signal transducers and activators of transcription expression and activity. J. Biol. Chem., 273, 31317-31326.
26. Wardell, S.E., Boonyaratanakornkit, V., Adelman, J.S., Aronheim, A. and Edwards, D.P. (2002) Jun dimerization protein 2 functions as a progesterone receptor N-terminal domain coactivator. Mol Cell Biol, 22, 5451-5466.
27. Tanoue, T., Adachi, M., Moriguchi, T. and Nishida, E. (2000) A conserved docking motif in MAP kinases common to substrates, activators and regulators. Nat. Cell Biol., 2, 110-116.
28. Tanoue, T. and Nishida, E. (2002) Docking interactions in the mitogen-activated protein kinase cascades. Pharmacol. Ther., 93, 193-202.
29. Enslen, H. and Davis, R.J. (2001) Regulation of MAP kinases by docking domains. Biol. Cell, 93, 5-14.
30. Beral, V. (2003) Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet, 362, 419-427.
31. Anderson, G.L., Limacher, M., Assaf, A.R., Bassford, T., Beresford, S.A., Black, H., Bonds, D., Brunner, R., Brzyski, R., Caan, B. et al. (2004) Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA, 291, 1701-1712.
32. Gregory, C.W., Fei, X., Ponguta, L.A., He, B., Bill, H.M., French, F.S. and Wilson, E.M. (2004) Epidermal growth factor increases coactivation of the androgen receptor in recurrent prostate cancer. J. Biol. Chem., 279, 7119-7130.
33. Wilson, G.R., Cramer, A., Welman, A., Knox, F., Swindell, R., Kawakatsu, H., Clarke, R.B., Dive, C. and Bundred, N.J. (2006) Activated c-SRC in ductal carcinoma in situ correlates with high tumour grade, high proliferation and HER2 positivity. Br. J. Cancer, 95, 1410-1414.
34. Steeg, P.S. and Zhou, Q. (1998) Cyclins and breast cancer. Breast Cancer Res. Treat., 52, 17-28.
35. Horwitz, K.B., Mockus, M.B. and Lessey, B.A. (1982) Variant T47D human breast cancer cells with high progesterone-receptor levels despite estrogen and antiestrogen resistance. Cell, 28, 633-642.
36. Sartorius, C.A., Groshong, S.D., Miller, A., Powell, R.L., Tung, L., Takimoto, G. and Horwitz, K. (1994) New T47D breast cancer cell lines for the independent study of progesterone B- and A-receptors; only antiprogestin- occupied B-receptors are switched to transcriptional agonists by cAMP. Cancer Res., 54, 3868-3877.
37. Gentleman, R.C., Carey, V.J., Bates, D.M., Bolstad, B., Dettling, M., Dudoit, S., Ellis, B., Gautier, L., Ge, Y., Gentry, J. et al. (2004) Bioconductor: open software development for computational biology and bioinformatics. Genome Biol., 5, R80.
38. Benjamini, Y. and Hochberg, Y. (1995) Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. R. Stat. Soc. Ser. B., 57, 289-300.
39. Mootha, V.K., Lindgren, C.M., Eriksson, K.F., Subramanian, A., Sihag, S., Lehar, J., Puigserver, P., Carlsson, E., Ridderstrale, M., Laurila, E. et al. (2003) PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat. Genet., 34, 267-273.
40. Subramanian, A., Tamayo, P., Mootha, V.K., Mukherjee, S., Ebert, B.L., Gillette, M.A., Paulovich, A., Pomeroy, S.L., Golub, T.R., Lander, E.S. et al. (2005) Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA, 102, 15545-15550.
41. Faivre, E.J. and Lange, C.A. (2007) Progesterone receptors upregulate Wnt-1 to induce epidermal growth factor receptor transactivation and c-Src-dependent sustained activation of Erk1/2 mitogen-activated protein kinase in breast cancer cells. Mol. Cell. Biol., 27, 466-480.
42. Faivre, E.J., Daniel, A.R., Hillard, C.J. and Lange, C.A. (2008) Progesterone receptor rapid signaling mediates serine 345 phosphorylation and tethering to specificity protein 1 transcription factors. Mol. Endocrinol., 22, 823-837.
43. Tanoue, T., Maeda, R., Adachi, M. and Nishida, E. (2001) Identification of a docking groove on ERK and p38 MAP kinases that regulates the specificity of docking interactions. EMBO J., 20, 466-479.
44. Groshong, S.D., Owen, G.I., Grimison, B., Schauer, I.E., Todd, M.C., Langan, T.A., Sclafani, R.A., Lange, C.A. and Horwitz, K.B. (1997) Biphasic regulation of breast cancer cell growth by progesterone: role of the cyclin-dependent kinase inhibitors, p21 and p27(Kip1). Mol. Endocrinol., 11, 1593-1607.
45. Musgrove, E.A., Lee, C.S. and Sutherland, R.L. (1991) Progestins both stimulate and inhibit breast cancer cell cycle progression while increasing expression of transforming growth factor alpha, epidermal growth factor receptor, c-fos, and c-myc genes. Mol. Cell. Biol., 11, 5032-5043.
46. Skildum, A., Faivre, E. and Lange, C.A. (2005) Progesterone receptors induce cell cycle progression via activation of mitogen activated protein kinases. Mol. Endocrinol., 19, 327-339.
47. Boonyaratanakornkit, V., Bi, Y., Cheskis, B., Mancini, M., Rudd, M., Buser, A., Rosen, J., Mukherjee, A., Lyndon, J. and Edwards, D. (2008) Keystone Symoposia on Molecular and Cellular Biology, Nuclear Receptors: Orphan Brothers and Steroid Sisters. Keystone Symposia, Whistler, British Columbia, p. 109.
48. Horwitz, K.B., Koseki, Y. and McGuire, W.L. (1978) Estrogen control of progesterone receptor in human breast cancer: role of estradiol and antiestrogen. Endocrinology, 103, 1742-1751.
49. Sartorius, C.A., Groshong, S.D., Miller, L.A., Powell, R.L., Tung, L., Takimoto, G.S. and Horwitz, K.B. (1994) New T47D breast cancer cell lines for the independent study of progesterone B- and Areceptors: only antiprogestin-occupied B-receptors are switched to transcriptional agonists by cAMP. Cancer Res., 54, 3868-3877.
50. Hagan, C.R., Daniel, A.R., Dressing, G.E. and Lange, C.A. (2012) Role of phosphorylation in progesterone receptor signaling and specificity. Mol. Cell. Endocrinol., 357, 43-49.
51. Daniel, A.R., Hagan, C.R. and Lange, C.A. (2011) Progesterone receptor action: defining a role in breast cancer. Expert Rev. Endocrinol. Metab., 6, 359-369.
52. Daniel, A.R., Knutson, T.P. and Lange, C.A. (2009) Signaling inputs to progesterone receptor gene regulation and promoter selectivity. Mol. Cell. Endocrinol., 308, 47-52.
53. Hagan, C.R., Daniel, A.R., Dressing, G.E. and Lange, C.A. (2012) Role of phosphorylation in progesterone receptor signaling and specificity. Mol. Cell. Endocrinol., 357, 43-49.
54. Castelli, M., Camps, M., Gillieron, C., Leroy, D., Arkinstall, S., Rommel, C. and Nichols, A. (2004) MAP kinase phosphatase 3 (MKP3) interacts with and is phosphorylated by protein kinase CK2alpha. J. Biol. Chem., 279, 44731-44739.
55. Cui, Y., Parra, I., Zhang, M., Hilsenbeck, S.G., Tsimelzon, A., Furukawa, T., Horii, A., Zhang, Z.Y., Nicholson, R.I. and Fuqua, S.A. (2006) Elevated expression of mitogen-activated protein kinase phosphatase 3 in breast tumors: a mechanism of tamoxifen resistance. Cancer Res., 66, 5950-5959.
56. Levinthal, D.J. and Defranco, D.B. (2005) Reversible oxidation of ERK-directed protein phosphatases drives oxidative toxicity in neurons. J. Biol. Chem., 280, 5875-5883.
57. Santos, S.J., Haslam, S.Z. and Conrad, S.E. (2008) Estrogen and progesterone are critical regulators of Stat5a expression in the mouse mammary gland. Endocrinology, 149, 329-338.
58. Brisken, C., Heineman, A., Chavarria, T., Elenbaas, B., Tan, J., Dey, S.K., McMahon, J.A., McMahon, A.P. and Weinberg, R.A. (2000) Essential function of Wnt-4 in mammary gland development downstream of progesterone signaling. Genes Dev., 14, 650-654.
59. Gavin, B.J. and McMahon, A.P. (1992) Differential regulation of the Wnt gene family during pregnancy and lactation suggests a role in postnatal development of the mammary gland. Mol. Cell. Biol., 12, 2418-2423.
60. Joshi, P.A., Jackson, H.W., Beristain, A.G., Di Grappa, M.A., Mote, P.A., Clarke, C.L., Stingl, J., Waterhouse, P.D. and Khokha, R. (2010) Progesterone induces adult mammary stem cell expansion. Nature, 465, 803-807.
61. Santos, S.J., Haslam, S.Z. and Conrad, S.E. (2010) Signal transducer and activator of transcription 5a mediates mammary ductal branching and proliferation in the nulliparous mouse. Endocrinology, 151, 2876-2885.
62. Subtil-Rodriguez, A., Millan-Arino, L., Quiles, I., Ballare, C., Beato, M. and Jordan, A. (2008) Progesterone induction of the 11beta-hydroxysteroid dehydrogenase type 2 promoter in breast cancer cells involves coordinated recruitment of STAT5A and progesterone receptor to a distal enhancer and polymerase tracking. Mol. Cell. Biol., 28, 3830-3849.
63. Ji, X., Li, W., Song, J., Wei, L. and Liu, X.S. (2006) CEAS: cisregulatory element annotation system. Nucleic Acids Res., 34, W551-W554.
64. Burgermeister, E., Chuderland, D., Hanoch, T., Meyer, M., Liscovitch, M. and Seger, R. (2007) Interaction with MEK causes nuclear export and downregulation of peroxisome proliferator activated receptor gamma. Mol. Cell. Biol., 27, 803-817.
65. Migliaccio, A., Piccolo, D., Castoria, G., Di Domenico, M., Bilancio, A., Lombardi, M., Gong, W., Beato, M. and Auricchio, F. (1998) Activation of the Src/p21ras/Erk pathway by progesterone receptor via cross-talk with estrogen receptor. EMBO J., 17, 2008-2018.
66. Olsten, M.E. and Litchfield, D.W. (2004) Order or chaos? An evaluation of the regulation of protein kinase CK2. Biochem. Cell Biol., 82, 681-693.
67. Caunt, C.J. and Keyse, S.M. (2013) Dual-specificity MAP kinase phosphatases (MKPs) : shaping the outcome of MAP kinase signalling. FEBS J., 280, 489-504.
68. Keyse, S.M. (2008) Dual-specificity MAP kinase phosphatases (MKPs) and cancer. Cancer Metastasis Rev., 27, 253-261.
69. Degl'Innocenti, D., Romeo, P., Tarantino, E., Sensi, M., Cassinelli, G., Catalano, V., Lanzi, C., Perrone, F., Pilotti, S., Seregni, E. et al. (2013) DUSP6/MKP3 is overexpressed in papillary and poorly differentiated thyroid carcinoma and contributes to neoplastic properties of thyroid cancer cells. Endocr. Relat. Cancer, 20, 23-37.
70. Chen, H.Y., Yu, S.L., Chen, C.H., Chang, G.C., Chen, C.Y., Yuan, A., Cheng, C.L., Wang, C.H., Terng, H.J., Kao, S.F. et al. (2007) A five-gene signature and clinical outcome in non-smallcell lung cancer. N. Engl. J. Med., 356, 11-20.
71. Croonquist, P.A., Linden, M.A., Zhao, F. and Van Ness, B.G. (2003) Gene profiling of a myeloma cell line reveals similarities and unique signatures among IL-6 response, N-ras-activating mutations, and coculture with bone marrow stromal cells. Blood, 102, 2581-2592.
72. Bloethner, S., Chen, B., Hemminki, K., Muller-Berghaus, J., Ugurel, S., Schadendorf, D. and Kumar, R. (2005) Effect of common B-RAF and N-RAS mutations on global gene expression in melanoma cell lines. Carcinogenesis, 26, 1224-1232.
73. Li, W., Song, L., Ritchie, A.M. and Melton, D.W. (2012) Increased levels of DUSP6 phosphatase stimulate tumourigenesis in a molecularly distinct melanoma subtype. Pigment Cell Melanoma Res., 25, 188-199.
74. Lucci, M.A., Orlandi, R., Triulzi, T., Tagliabue, E., Balsari, A. and Villa-Moruzzi, E. (2010) Expression profile of tyrosine phosphatases in HER2 breast cancer cells and tumors. Cell. Oncol., 32, 361-372.
75. Lonne, G.K., Masoumi, K.C., Lennartsson, J. and Larsson, C. (2009) Protein kinase Cdelta supports survival of MDA-MB-231 breast cancer cells by suppressing the ERK1/2 pathway. J. Biol. Chem., 284, 33456-33465.
76. Quyun, C., Ye, Z., Lin, S.C. and Lin, B. (2010) Recent patents and advances in genomic biomarker discovery for colorectal cancers. Recent Pat. DNA Gene Seq., 4, 86-93.
77. MacKeigan, J.P., Murphy, L.O. and Blenis, J. (2005) Sensitized RNAi screen of human kinases and phosphatases identifies new regulators of apoptosis and chemoresistance. Nat. Cell Biol., 7, 591-600.
78. Furukawa, T., Fujisaki, R., Yoshida, Y., Kanai, N., Sunamura, M., Abe, T., Takeda, K., Matsuno, S. and Horii, A. (2005) Distinct progression pathways involving the dysfunction of DUSP6/MKP-3 in pancreatic intraepithelial neoplasia and intraductal papillary-mucinous neoplasms of the pancreas. Mod Pathol, 18, 1034-1042.
79. Messina, S., Frati, L., Leonetti, C., Zuchegna, C., Di Zazzo, E., Calogero, A. and Porcellini, A. (2011) Dual-specificity phosphatase DUSP6 has tumor-promoting properties in human glioblastomas. Oncogene, 30, 3813-3820.
80. Madak-Erdogan, Z., Lupien, M., Stossi, F., Brown, M. and Katzenellenbogen, B.S. (2011) Genomic collaboration of estrogen receptor alpha and extracellular signal-regulated kinase 2 in regulating gene and proliferation programs. Mol. Cell. Biol., 31, 226-236.
81. Jozwik, K.M. and Carroll, J.S. (2012) Pioneer factors in hormone-dependent cancers. Nat. Rev. Cancer, 12, 381-385.
82. Magnani, L., Eeckhoute, J. and Lupien, M. (2011) Pioneer factors: directing transcriptional regulators within the chromatin environment. Trends Genet., 27, 465-474.
83. Carroll, J.S., Liu, X.S., Brodsky, A.S., Li, W., Meyer, C.A., Szary, A.J., Eeckhoute, J., Shao, W., Hestermann, E.V., Geistlinger, T.R. et al. (2005) Chromosome-wide mapping of estrogen receptor binding reveals long-range regulation requiring the forkhead protein FoxA1. Cell, 122, 33-43.
84. Magnani, L., Ballantyne, E.B., Zhang, X. and Lupien, M. (2011) PBX1 genomic pioneer function drives ERalpha signaling underlying progression in breast cancer. PLoS Genet., 7, e1002368.
85. Mohammed, H., D'Santos, C., Serandour, A.A., Ali, H.R., Brown, G.D., Atkins, A., Rueda, O.M., Holmes, K.A., Theodorou, V., Robinson, J.L. et al. (2013) Endogenous purification reveals GREB1 as a key estrogen receptor regulatory factor. Cell Rep., 3, 342-349.
86. Tan, S.K., Lin, Z.H., Chang, C.W., Varang, V., Chng, K.R., Pan, Y.F., Yong, E.L., Sung, W.K. and Cheung, E. (2011) AP-2gamma regulates oestrogen receptor-mediated long-range chromatin interaction and gene transcription. EMBO J., 30, 2569-2581.
87. Santos, S.J., Haslam, S.Z. and Conrad, S.E. (2010) Signal transducer and activator of transcription 5a mediates mammary ductal branching and proliferation in the nulliparous mouse. Endocrinology, 151, 2876-2885.
88. Meier-Abt, F., Milani, E., Roloff, T., Brinkhaus, H., Duss, S., Meyer, D.S., Klebba, I., Balwierz, P.J., van Nimwegen, E. and Bentires-Alj, M. (2013) Parity induces differentiation and reduces Wnt/Notch signaling ratio and proliferation potential of basal stem/progenitor cells isolated from mouse mammary epithelium. Breast Cancer Res., 15, R36.
89. Howe, L.R. and Brown, A.M. (2004) Wnt signaling and breast cancer. Cancer Biol. Ther., 3, 36-41.
90. Lin, S.Y., Xia, W., Wang, J.C., Kwong, K.Y., Spohn, B., Wen, Y., Pestell, R.G. and Hung, M.C. (2000) Beta-catenin, a novel prognostic marker for breast cancer: its roles in cyclin D1 expression and cancer progression. Proc. Natl Acad. Sci. USA, 97, 4262-4266.
91. Collu, G.M., Meurette, O. and Brennan, K. (2009) Is there more to Wnt signalling in breast cancer than stabilisation of beta-catenin? Breast Cancer Res., 11, 105.
92. Tanos, T., Sflomos, G., Echeverria, P.C., Ayyanan, A., Gutierrez, M., Delaloye, J.F., Raffoul, W., Fiche, M., Dougall, W., Schneider, P. et al. (2013) Progesterone/RANKL Is a Major Regulatory Axis in the Human Breast. Science translational medicine, 5, 182ra155.
93. Mote, P.A., Bartow, S., Tran, N. and Clarke, C.L. (2002) Loss of co-ordinate expression of progesterone receptors A and B is an early event in breast carcinogenesis. Breast Cancer Res Treat, 72, 163-172.
94. Mote, P.A., Balleine, R.L., McGowan, E.M. and Clarke, C.L. (1999) Colocalization of progesterone receptors A and B by dual immunofluorescent histochemistry in human endometrium during the menstrual cycle. J Clin Endocrinol Metab, 84, 2963-2971.
95. Mote, P.A., Graham, J.D. and Clarke, C.L. (2007) Progesterone receptor isoforms in normal and malignant breast. Ernst Schering Found Symp Proc, 77-107.
96. Graham, J.D., Yeates, C., Balleine, R.L., Harvey, S.S., Milliken, J.S., Bilous, A.M. and Clarke, C.L. (1995) Characterization of progesterone receptor A and B expression in human breast cancer. Cancer Res, 55, 5063-5068.
97. Pathiraja, T.N., Shetty, P.B., Jelinek, J., He, R., Hartmaier, R., Margossian, A.L., Hilsenbeck, S.G., Issa, J.P. and Oesterreich, S. (2011) Progesterone receptor isoform-specific promoter methylation: association of PRA promoter methylation with worse outcome in breast cancer patients. Clinical cancer research: an official journal of the American Association for Cancer Research, 17, 4177-4186.